3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
NETWORK
4
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
2
Conditions
Squamous Cell Carcinoma of Head and Neck
2
Virus Diseases
1
Tumor Virus Infections
1
Pharyngeal Diseases
1
Papillomavirus Infections
1
Otorhinolaryngologic Neoplasms
1
Otorhinolaryngologic Diseases
1
Oropharyngeal Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Head and Neck Neoplasms
1
DNA Virus Infections
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Interventions
Cyclophosphamide
2042
Radiotherapy
1859
Cisplatin
1825
Carboplatin
1533
Gemcitabine
1434
Paclitaxel
1289
Bevacizumab
1270
Docetaxel
1202
pembrolizumab
1198
Oxaliplatin
1160
Capecitabine
1142
Fluorouracil
1061
Dexamethasone
971
Rituximab
919
Nivolumab
908
Magnetic Resonance Spectroscopy
862
Etoposide
839
Doxorubicin
823
Drug Therapy
792
Radiosurgery
776
Irinotecan
775
Cytarabine
736
fludarabine
716
Leucovorin
676
Lenalidomide
608
fludarabine phosphate
564
Temozolomide
552
Radiation
541
Filgrastim
540
Cetuximab
537
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Interventional
×
Nimorazole
×
Clear all
NCT04124198
2025-12-31
QoLATI
Rigshospitalet, Denmark
Phase NA
Active not recruiting
138 enrolled
NCT01950689
2021-10-19
NIMRAD
The Christie NHS Foundation Trust
Phase 3
Completed
338 enrolled